Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriFol-B is a branded nutraceutical combination product marketed by Sugen Pharma, an Ahmedabad-based pharmaceutical company. It is primarily formulated for use in obstetrics and gynecology to support healthy pregnancy, prevent fetal deformities (such as neural tube defects), and manage hyperhomocysteinemia. The product typically contains the bioactive forms of essential B-vitamins: **L-methylfolate** (the active form of Vitamin B9), **methylcobalamin** (the active form of Vitamin B12), **pyridoxal-5-phosphate** (the active form of Vitamin B6), and **biotin** (Vitamin B7). By providing these vitamins in their metabolically active states, TriFol-B bypasses the enzymatic conversion steps required by synthetic folic acid and cyanocobalamin, ensuring optimal bioavailability even in individuals with genetic polymorphisms like MTHFR mutations. It plays a critical role in the one-carbon metabolism cycle, facilitating DNA synthesis and the conversion of homocysteine to methionine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TriFol-B.